Filing Flows › Comparisons › COCP vs IBIO
Cocrystal Pharma vs iBio: COCP and IBIO compared
Cocrystal Pharma is the larger company: $105K of revenue in its latest quarter (Q2 2026) against $100K for iBio (Q1 FY26).
Where the money goes: COCP and IBIO
Cocrystal Pharma (COCP) · Q2 2026
Cocrystal Pharma, Q2 2026: revenue $105K, net loss $3.2M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
iBio (IBIO) · Q1 FY26
iBio, Q1 FY26: revenue $100K, net loss $5.7M, operating cash flow −$5.7M. The chart follows the revenue to costs, profit and cash.
| Cocrystal Pharma (COCP) | iBio (IBIO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 FY26 |
| Revenue | $105K | $100K |
| Operating margin | n/m | n/m |
| Net earnings | −$3.2M | −$5.7M |
| Operating cash flow | −$2.5M | −$5.7M |
Questions
Which is bigger, Cocrystal Pharma or iBio?
Cocrystal Pharma is the larger company: $105K of revenue in its latest quarter (Q2 2026) against $100K for iBio (Q1 FY26).
More: Cocrystal Pharma earnings · how Cocrystal Pharma makes money · iBio earnings · how iBio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 13, 2026; 10-Q filed Nov 12, 2025). Fiscal quarters can end on different dates. Not investment advice.